NCT02898077

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 440 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.

Conditions

• Gastroesophageal Junction Adenocarcinoma
• Gastric Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV
DRUG	Paclitaxel	Administered IV
DRUG	Placebo	Administered IV

Timeline

• Start date: 2017-03-02
• Primary completion: 2020-06-30
• Completion: 2021-04-12
• First posted: 2016-09-13
• Last updated: 2022-06-14
• Results posted: 2021-08-03

Locations

32 sites across 4 countries: China, Malaysia, Philippines, Thailand

Regulatory

• FDA-regulated drug study